2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
C. Zhou, Meghna Das Thakur, Manoj Srivastava, Wen Zou, Hongjie Xu, M. Ballinger, Enriqueta Felip, Heather A. Wakelee, Nasser K. Altorki, Martin Reck, Rüediger Liersch, Anna Kryzhanivska, M. Harada, Hiroshi Tanaka, John Hamm, Steve McCune, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Silvia Novello
Topics & Concepts
MedicineAtezolizumabOncologyInternal medicineAdjuvantAdjuvant chemotherapyChemotherapyStage (stratigraphy)Distributed File SystemCancerImmunotherapyBreast cancerPembrolizumabComputer securityPaleontologyComputer scienceBiologyCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies